GRDN

AI MemoPost-earnings T+1

Guardian Pharmacy Services

As of 2026-08-07/Post-earnings T+1/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-07 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 beat and raised FY2026 guidance • 2026-08-07

Expected move: +19%

Biggest risk

Reported revenue growth remains muted by IRA pricing reductions, and execution risk increases with the Wellness Concepts integration, Lexington greenfield launch, and recent leadership changes. Analyst target revisions and consensus-surprise detail are unavailable in the packet.

Invalidation

Break below $34 or thesis failure.

What would change my mind?

The post-earnings setup is constructive: adjusted EBITDA rose year over year, residents served grew 8%, cash was $89.8M, and the company reported no long-term debt outstanding under its credit facility. Raised FY2026 guidance supports positive forward momentum.

Research note

Recommendation

—

Confidence

high

As of

2026-08-07

Base target

$47

p=55%

Bull target

$54

p=25%

Bear target

$34

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

IRA pricing and reimbursement pressure
Resident growth and footprint expansion
The post-earnings setup is constructive: adjusted EBITDA rose year over year, residents served grew 8%, cash was $89.8M, and the company reported no long-term debt outstanding under its credit facility.

BearKey bullets

Acquisition integration, greenfield execution, and recently changed senior leadership create operational risk.
Analyst estimate revisions, target changes, and detailed consensus-surprise data are unavailable.
Guidance excludes future acquisitions, limiting visibility into acquisition-driven upside.

WatchKey bullets

Q2 beat and raised FY2026 guidance

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $47 (p=55%)

Bull/Bear spread: +37% / -14%

Vs latest close: Bull +37% · Base +19% · Bear -14%

Scenario probabilities

Bull Target: $54 (p=25%)Base Target: $47 (p=55%)Bear Target: $34 (p=20%)

Commentary

Primary earnings evidence is positive, with raised guidance and strong adjusted EBITDA growth. The stock was reported by the finance feed at $44.11 on August 7, up 11.8% from the prior close, indicating a favorable immediate market reaction. Analyst revisions and social coverage are unavailable, so conviction remains moderate rather than high.

As of 2026-08-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

IRA pricing and reimbursement pressure
Resident growth and footprint expansion

Scenarios

Bull Target (Scenario probability)

$54 / p=25% prob

Base Target (Scenario probability)

$47 / p=55% prob

Bear Target (Scenario probability)

$34 / p=20% prob

Price $39 as of 2026-08-06

Nearest Scenario: Bear (∆ 14%)

Targets vs latest close: Bull +37% · Base +19% · Bear -14%

Sentiment & Exposure

News Sentiment (30d)

0.80

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-07
Q2 beat and raised FY2026 guidance
Q2 revenue was $351.8M, adjusted EBITDA $29.7M, and diluted EPS $0.34; management raised FY2026 revenue guidance to $1.43B-$1.45B and adjusted EBITDA guidance to $129M-$131M. [#SEC-8K-2026-08-06]
Prob 100.00% • Move 8.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

IRA pricing and reimbursement pressure
2026-11-05
Management said IRA-related pricing reductions constrained reported revenue growth to 2%, although underlying revenue growth would have been low double digits absent the reductions. Ongoing payor and reimbursement changes remain a downside risk. [#SEC-8K-2026-08-06]
Prob 60% • Move -8% • Priced-in 55%

Long-term Catalysts

Months to a year

Resident growth and footprint expansion
2027-08-07
Residents served reached approximately 210,000, up 8% year over year. The company also completed the Wellness Concepts acquisition and launched a Lexington, Kentucky greenfield pharmacy. [#SEC-8K-2026-08-06]
Prob 65% • Move 15% • Priced-in 35%

Risks

Acquisition integration, greenfield execution, and recently changed senior leadership create operational risk.
Analyst estimate revisions, target changes, and detailed consensus-surprise data are unavailable.
Guidance excludes future acquisitions, limiting visibility into acquisition-driven upside.
IRA-related pricing reductions and broader reimbursement changes can suppress reported growth.
Payor disputes and settlements may create earnings volatility; Q2 included an $8.5M settlement.

Peers

Symbol	Summary
AXGN	Same-sector, similar market-cap reference, but a medical-device company and not a close LTC pharmacy-services peer.
NEOG	Similar market-cap health-care reference, but product exposure differs materially from Guardian's pharmacy-services model.
ABT	Large diversified health-care comparator; useful only as a broad sector benchmark, not a direct operating peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-07

AI Stock Memo: GRDN - Guardian Pharmacy Services - RankAlpha